Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
Kamal Pandey, Nahee Park, Kyung‐Soon Park, et al.
Cancers (2020) Vol. 12, Iss. 12, pp. 3566-3566
Open Access | Times Cited: 100

Showing 1-25 of 100 citing articles:

Kinase drug discovery 20 years after imatinib: progress and future directions
Philip Cohen, Darren A.E. Cross, Pasi A. Jänne
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 7, pp. 551-569
Open Access | Times Cited: 781
Exploiting senescence for the treatment of cancer
Liqin Wang, Lina Lankhorst, René Bernards
Nature reviews. Cancer (2022) Vol. 22, Iss. 6, pp. 340-355
Open Access | Times Cited: 518
The Cancer SENESCopedia: A delineation of cancer cell senescence
Fleur Jochems, Bram Thijssen, Giulia De Conti, et al.
Cell Reports (2021) Vol. 36, Iss. 4, pp. 109441-109441
Open Access | Times Cited: 137
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
Laura Morrison, Sibylle Loibl, Nicholas C. Turner
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 2, pp. 89-105
Closed Access | Times Cited: 109
Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer
Martina Troiani, Manuel Colucci, Mariantonietta D’Ambrosio, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 80
A review on the role of cyclin dependent kinases in cancers
Soudeh Ghafouri‐Fard, Tayyebeh Khoshbakht, Bashdar Mahmud Hussen, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 80
Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
Florencia P. Madorsky Rowdo, Rachel Martini, Sarah Ackermann, et al.
Cancer Research (2025) Vol. 85, Iss. 3, pp. 551-566
Open Access | Times Cited: 2
Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer
Uzma Asghar, Ruhi Kanani, Rebecca Roylance, et al.
JCO Precision Oncology (2022), Iss. 6
Open Access | Times Cited: 66
Targeting senescence as an anticancer therapy
Laura Bousset, Jesús Gil
Molecular Oncology (2022) Vol. 16, Iss. 21, pp. 3855-3880
Open Access | Times Cited: 59
CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition
Sung Soo Kim, Alessandra Leong, Minah Kim, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 55
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
Abeer J. Al-Qasem, Carla L. Alves, Sidse Ehmsen, et al.
npj Precision Oncology (2022) Vol. 6, Iss. 1
Open Access | Times Cited: 43
Escape from senescence: molecular basis and therapeutic ramifications
Konstantinos Evangelou, Konstantinos Belogiannis, Angelos Papaspyropoulos, et al.
The Journal of Pathology (2023) Vol. 260, Iss. 5, pp. 649-665
Open Access | Times Cited: 27
CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective
Fiona H. Zhou, Teesha Downton, Allegra Freelander, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 25
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
Antonino Glaviano, Seth A. Wander, Richard D. Baird, et al.
Drug Resistance Updates (2024) Vol. 76, pp. 101103-101103
Open Access | Times Cited: 14
Seize the engine: Emerging cell cycle targets in breast cancer
Jesús Fuentes‐Antrás, Philippe L. Bédard, David W. Cescon
Clinical and Translational Medicine (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer
Jessica Armand, Sungsoo Kim, Jae Hyun Kim, et al.
(2025)
Open Access | Times Cited: 1
Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines
Bashir Lawal, Yen‐Lin Liu, Ntlotlang Mokgautsi, et al.
Biomedicines (2021) Vol. 9, Iss. 1, pp. 92-92
Open Access | Times Cited: 51
Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
Erin R. Scheidemann, Ayesha N. Shajahan‐Haq
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 22, pp. 12292-12292
Open Access | Times Cited: 44
CDK4/6 inhibitors: a brief overview and prospective research directions
Tenzin Adon, Dhivya Shanmugarajan, Honnavalli Yogish Kumar
RSC Advances (2021) Vol. 11, Iss. 47, pp. 29227-29246
Open Access | Times Cited: 42
Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer
Marios Papadimitriou, Anastasia Pazaiti, Konstantinos Iliakopoulos, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2022) Vol. 1869, Iss. 12, pp. 119346-119346
Open Access | Times Cited: 35
Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
Ioana-Miruna Stanciu, Andreea Paroşanu, Cristina Orlov‐Slavu, et al.
Diagnostics (2023) Vol. 13, Iss. 5, pp. 987-987
Open Access | Times Cited: 21
Senescence-related gene c-Myc affects bladder cancer cell senescence by interacting with HSP90B1 to regulate cisplatin sensitivity
Yaxuan Wang, Haixia Zhu, Haifei Xu, et al.
Aging (2023)
Open Access | Times Cited: 21
Irreversible cell cycle exit associated with senescence is mediated by constitutive MYC degradation
Marwa M. Afifi, Adrijana Crncec, James A. Cornwell, et al.
Cell Reports (2023) Vol. 42, Iss. 9, pp. 113079-113079
Open Access | Times Cited: 21
Insights into the role of senescence in tumor dormancy: mechanisms and applications
Valerie DeLuca, Tareq Saleh
Cancer and Metastasis Reviews (2023) Vol. 42, Iss. 1, pp. 19-35
Closed Access | Times Cited: 19
Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer
Sung Soo Kim, Jessica Armand, Anton Safonov, et al.
Cell Reports (2023) Vol. 42, Iss. 11, pp. 113198-113198
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top